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Abstract To assess the capability of perfusion MRI to
differentiate between necrosis and tumor recurrence in
patients showing radiological progression of cerebral
metastases treated with stereotactic radiosurgery (SRS).
From 2004 to 2006 dynamic susceptibility-weighted con-
trast-enhanced perfusion MRI scans were performed on
patients with cerebral metastasis showing radiological
progression after SRS during follow-up. Several perfusion
MRI characteristics were examined: a subjective visual
score of the relative cerebral blood volume (rCBV) map
and quantitative rCBV measurements of the contrast-
enhanced areas of maximal perfusion. For a total of 34
lesions in 31 patients a perfusion MRI was performed.
Diagnoses were based on histology, definite radiological
decrease or a combination of radiological and clinical
follow-up. The diagnosis of tumor recurrence was obtained
in 20 of 34 lesions, and tumor necrosis in 14 of 34.
Regression analyses for all measures proved statistically
significant (v2 = 11.6–21.6, P \ 0.001–0.0001). Visual
inspection of the rCBV map yielded a sensitivity and
specificity of 70.0 respectively 92.9%. The optimal cutoff
point for maximal tumor rCBV relative to white matter was
2.00 (improving the sensibility to 85.0%) and 1.85 relative
to grey matter (GM), improving the specificity to 100%,
with a corresponding sensitivity of 70.0%. Perfusion MRI
seems to be a useful tool in the differentiation of necrosis
and tumor recurrence after SRS. For the patients displaying
a rCBV-GM greater than 1.85, the diagnosis of necrosis
was excluded. Salvage treatment can be initiated for these
patients in an attempt to prolong survival.
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Introduction
Cerebral metastases affect 20–30% of all cancer patients
and form the second most common cerebral neoplasm in
adults [1, 2]. Stereotactic radiosurgery (SRS), either as a
single modality or in combination with whole brain
radiotherapy (WBRT), is an established treatment option
for patients with a limited number of brain metastases,
increasing the mean overall survival rate from 3 to
6 months after WBRT to approximately 8–12 months [1,
15, 22, 33, 34]. Radiation-induced changes on follow-up
MRI studies have been reported in up to 22% of patients,
and are frequently impossible to differentiate from local
tumor progression [18, 35, 37, 39, 44, 50, 51]. In case of
local tumor recurrence, surgical resection or repeat radio-
surgery can be considered as salvage options for selected
patients who are in good clinical condition and have stable
or absent extracranial disease, underscoring the clinical
relevance of this diagnostic dilemma.
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Histological verification of recurrence constitutes the
gold standard, but this requires a resection of the lesion
rather than biopsy for reasons of spatial heterogeneity, i.e.,
regions of viable tumor and necrosis may co-exist after
SRS. Several non-invasive techniques, including SPECT,
MR spectroscopy (HMRS) and PET, have been used to
differentiate between radionecrosis and tumor progression
[11, 17, 43, 47]. For FDG-PET, sensitivities between 65
and 86% (with MRI co-registration) and for HMRS and
SPECT sensitivities and specificities around 85%-90% are
reported, favoring SPECT [5, 11, 18, 19]. Besides the
financial and labor-intensive aspects of these techniques,
one of the major disadvantages is that the relatively low
resolution might prevent (early) detection of recurrence in
these heterogenous lesions [12]. Recent MRI techniques
with higher spatial resolution have been suggested to yield
better results [48, 52].
Dynamic susceptibility-weighted contrast-enhanced
(DSC) or perfusion MRI is capable of quantifying micro-
vessel density (vascularity) and permeability of brain tissue
by assessment of the relative cerebral blood volume
(rCBV) [3, 8, 10, 25, 27, 38, 46] and has been used for
grading, histological differentiation and assessment of
prognosis in glioma patients [6, 7, 16, 24, 29, 32, 54]. The
literature on the use of DSC MRI for brain metastases is
limited and mainly focuses on predicting treatment
response [23, 48, 53].
The goal of this study is to evaluate the capability of
perfusion MRI for differentiating between radiation-
induced tumor necrosis and tumor progression in patients
with radiosurgically treated cerebral metastases with pro-
gressive lesions during follow-up in the presence of salvage
options.
Methods and materials
Patient population
At the VU University Medical Center Amsterdam, patients
with one to three brain metastases have been treated with
SRS as a single modality since 2002. The SRS dose varied
between 18 and 21 Gy prescribed at the 80% isodose,
depending on the size of the treated lesion. The SRS-alone
treatment option was combined with standardized MRI
follow-up at 3-month intervals in order to allow for timely
salvage therapy, when indicated. Those patients demon-
strating a progression in volume of the treated lesion during
follow-up and who were candidates for salvage therapy in
the form of surgery or repeat SRS based on their general
condition and extracranial tumor status routinely under-
went a perfusion MRI to differentiate between radiation-
induced tumor necrosis and tumor recurrence.
A total of 31 such patients harboring 34 treated lesions
form the basis of this study. Relevant patient and treatment
characteristics are shown in Table 1. The majority of
patients (19/31) had metastases from lung cancer. The pre-
radiosurgery metastasis volume ranged from 0.6 to
31.6 cm3 (mean 8.0 cm3). The mean volume after radio-
surgery (prior to progression, i.e., the minimum volume
measured during follow-up) was 3.2 cm3 (range 0.1–
10.7 cm3). The corresponding volume at the time of pro-
gression (and of the perfusion MRI) was 7.2 cm3 (range
0.2–25.3 cm3). The median SRS dose was 21 Gy, pre-
scribed at the 80% isodose. Four patients had received
WBRT prior to SRS with a total dose of 20 Gy in five
fractions of 4 Gy.
Clinical outcome
Although histopathological verification is the gold standard
in differentiating between tumor recurrence or radiation-
induced tumor necrosis, this was available in only a small
subgroup. In addition, some patients showed a substantial
regression of lesion volume on subsequent follow-up MRI
scans without additional treatment, making a diagnosis of
tumor necrosis highly likely, and of tumor recurrence very
unlikely. In all other patients, the clinical diagnosis was
assessed subjectively using radiological and clinical follow-
up data. A rapidly deteriorating neurological condition,
short survival time due to neurological progression, or
ongoing progression in subsequent MRI scans was consid-
ered indicative of tumor progression. All clinical diagnoses
were defined retrospectively by the treating physician (FL),
who was blinded to the perfusion MRI findings.
MRI
Imaging was performed on a 1.5-T MRI scanner (Siemens
Sonata, Siemens Medical Systems, Erlangen, Germany).
After a localizing sagittal T1-weighted image, non-
enhanced axial T1-weighted spin echo [repetition time/
echo time (TR/TE) 600/12 ms] and axial T2-weighted
(3,680/85) images were obtained. Post-contrast axial and
sagittal (MPR) T1-weighted imaging was performed after
the acquisition of the DSC MRI data.
DSC MRI scans were acquired with a gradient-echo
echoplanar imaging (GE-EPI) technique during the first pass
of a standard dose (0.1 mmol/kg) bolus of gadolinium con-
trast (Magnevist; Berlex Laboratories). Imaging parameters
were: TR/TE 1,440/47; slice thickness 5 mm, interslice gap
1.5 mm, field of view 230–230 mm, matrix 128–128 leading
to pixel size 0.9–0.9 mm (after interpolation), flip angle 90,
and signal bandwidth, 1,345 Hz/pixel. The injection rate of
the contrast was 5 ml/s. A total of 50 images were acquired at
1.44-s intervals with the bolus typically arriving between the
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10th and 15th image. The post-processing of the DSC MRI
data were performed on a Leonardo VD10B Syngo OEM
installation (Siemens AG).
DSC measurements
The DSC MRI scans were scored based on both subjective
and objective evaluations of the rCBV maps by an
experienced neuroradiologist (E.S.), who was blinded with
respect to the clinical information and outcome.
Subjective scoring of the rCBV maps
The rCBV map was evaluated alongside the post-contrast
structural MRI series. A subjective diagnosis of ‘‘tumor
progression’’ was based on the presence of nodular highly
Table 1 Patient characteristics and perfusion measures
Patient Metastasis Initial prior TTP PPS OS Clinical rCBV rCBV map
Sex Age Prim. tumor Vol (cc) Dose Therapy Diagnosis WM GM Diagnosis
1 M 54 Lung 19.8 24 None 10 6.5 16.8 Necrosis 1.57 0.62 Necrosis
2 M 68 Lung 10.5 21 NSR ? RTH 4 1 5.2 Progression 2.31 0.99 Progression
3 M 57 Lung 1.1 21 BPY ? RTH 8.5 16.5 25.2 Progression* 4.69 2.66 Progression
4 F 66 Lung 7.1 24 None 6 2 8.2 Necrosis 0.94 0.48 Necrosis
5 M 43 Lung 5.8 18 NSR 3 17.5 20.6 Progression* 6.72 5.16 Progression
6 F 47 Lung 3.0 21 None 17 20 36.6 Necrosisa 1.50 0.78 Non concl.
7a M 44 Lung 13.6 18 None 12 12 23.9 Progression 4.15 1.99 Progression
7b M 44 Lung 2.6 18 None 12 12 23.9 Necrosisa 3.87 1.85 Non concl.
8 M 43 Lung 3.8 21 None 7.5 6 13.7 Necrosis 0.94 0.47 Non concl.
9 F 56 Lung 18.9 24 RTH 11 9 20.0 Progression 4.73 3.49 Progression
10 F 58 Lung 5.8 18 None 9 20 29.2 Necrosisa 1.64 0.60 Necrosis
11 F 72 Lung 9.2 21 None 3.5 1.5 4.9 Progression 0.97 0.55 Necrosis
12 F 47 Lung 6.4 18 None 7.5 20.5 28.0 Necrosisa 3.09 0.59 Necrosis
13 M 45 Lung 13.0 24 None 7 4.5 11.9 Necrosis 1.98 1.09 Necrosis
14 F 72 Lung 1.7 15 None 7.5 11.5 19.3 Necrosis 3.71 1.47 Necrosis
15 M 58 Lung 8.4 18 RTH 6 1.5 7.6 Progression 2.04 1.95 Necrosis
16 F 57 Lung 0.9 21 None 7.5 3 10.3 Progression* 2.80 0.78 Necrosis
17 F 62 Lung 10.7 18 None 6.5 7 13.5 Progression 3.90 2.29 Progression
18 F 41 Lung 12.7 24 None 4 6.5 10.5 Progression* 4.67 2.22 Progression
19 M 70 Lung 3.9 18 None 8.5 5 13.6 Progression 2.58 1.45 Non concl.
20 F 51 Mamma 9.1 18 None 9.5 7 16.8 Progression 4.19 2.32 Progression
21 F 36 Mamma 10.6 18 NSR 11.5 12.5 24.2 Necrosis 2.31 1.33 Necrosis
22 F 51 Mamma 8.1 18 None 7 22 28.8 Progression* 13.69 5.74 Progression
23 F 36 Mamma 1.3 15 None 7 28 35.5 Necrosisa 1.24 0.92 Non concl.
24 F 46 Mamma 0.6 21 NSR 15 24 38.6 Progression 6.22 2.67 Progression
25a F 54 Ovary 4.1 18 None 7.5 4 11.8 Progression 2.40 1.86 Progression
25b F 54 Ovary 1.2 18 None 7.5 4 11.8 Progression* 5.86 4.54 Progression
25c F 54 Ovary 15.4 18 None 7.5 4 11.8 Progression 1.23 0.95 Necrosis
26 M 53 Melanoma 20.8 24 None 9 5.5 14.4 Progression 7.84 4.66 Progression
27 F 62 Melanoma 3.3 21 None 12 1 12.9 Progression 0.75 0.31 Necrosis
28 F 60 Renal cell 3.8 21 None 7.5 3 10.6 Necrosis 1.56 1.17 Progression
29 M 59 Renal cell 3.2 21 None 7 7.5 14.7 Progression 4.21 2.77 Progression
30 M 49 Bladder 31.6 24 None 9.5 3.5 13.2 Necrosis 0.55 0.55 Non concl.
31 F 56 Colon 0.9 21 None 8 16 23.9 Necrosis 0.47 0.29 Necrosis
The first columns show the most important patient characteristics; the last three show the different perfusion parameters. Age is in years; dose is
radiation dose in Grays at the 80% isodose center; survival times are in months. NSR neurosurgical resection, BPY biopsy, RTH radiotherapy,
TTP time to (radiological) progression, OS overall survival time, PPS survival time after radiological progression. rCBV relative cerebral blood
volume, WM white matter, GM grey matter, non concl non-conclusive. *Diagnosis based on histology, adiagnosis based on radiological decrease
at follow-up
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vascularized areas within the contrast-enhanced lesion,
irrespective of areas indicative of necrosis (Fig. 1a), relative
to the contralateral hemisphere. Alternatively, a diagnosis of
‘‘tumor necrosis’’ was made in case of a clear absence of
perfusion (black hole), in the absence of any nodular highly
vascularized area (Fig. 1b). When neither a high perfusion
area nor a clear perfusion absence could be determined, the
rCBV map was scored as ‘‘non-conclusive.’’
rCBV measurements
The procedure used to calculate rCBV from DSC MRI data
is based on standard algorithms. The principles of calcu-
lating rCBV from signal intensity curves during the first
pass of a bolus contrast agent have been described exten-
sively by others [14, 20]. Since spatial heterogeneity is a
possible confounding factor in recurrent lesions, rCBVs
were calculated for the highest perfusion fraction, irre-
spective of whether that area was judged as being actually
high relative to contralateral white or grey matter, in con-
cordance with previous reports [24, 26, 55]. In addition, as
irradiated tumor rCBVs typically lie between white matter
and grey matter values [17], a mean grey matter CBV,
calculated from three regions Of interest (ROIs) spread
over the contralateral cortex (one frontal, one temporal and
one occipital) after exclusion of large vessels to minimize
the chances of partial volume of white matter voxels [28]
was used as a reference region in addition to a contralateral
white matter reference region (semioval center). Thus, two
quantitative parameters were calculated: rCBV-WM and
rCBV-GM.
Statistical methods
Kaplan–Meyer statistics and the log-rank test were used for
a survival analysis of the different clinical diagnosis
groups. Logistic regression models were fitted for evalua-
tion of the value of the subjective and objective rCBV map
conclusions for predicting the clinical diagnosis. For all
objective/quantitative measures, ROC curves were plotted
to calculate the most discriminative cutoff point with an
optimal area under the curve and to define the clinically
most relevant combination of sensitivity, specificity and
accuracy. All statistical evaluations were computed using
SPSS 12.0.1 for Windows, released November 2003,
Copyright  SPSS Inc., 1989–2003.
Results
Clinical outcome
In 6 of the 34 lesions (18%), a histological diagnosis was
obtained (1 post-mortem), and all showed viable tumor on
pathological examination. Five lesions (15%) showed
subsequent spontaneous radiological regression without
treatment, indicative of tumor necrosis. Thus, an objective
outcome parameter could be obtained for 11 lesions (35%).
For the remaining 23 lesions, the clinical diagnosis was
assigned as tumor recurrence in 14 lesions and tumor
necrosis in 9 lesions, based retrospectively on radiological
follow-up and clinical course. In total, 20 lesions (59%)
Fig. 1 rCBV maps and T1-weighted scans after gadolinium admin-
istration. Patient A shows a clear high rCBV at the site of the contrast-
enhanced lesion (Fig. 1a, arrow), suggestive of tumor recurrence. The
lesion was resected, and the histological diagnosis was tumor
recurrence. Patient B displays a perfusion absence (Fig. 1b, ‘‘black
spot,’’ arrow), suggestive of necrosis, at the lesion site as indicated by
the post-contrast scan. This was confirmed by clinical and radiolog-
ical follow-up. For the last patient (C) the rCBV map was judged
‘‘inconclusive,’’ since no clear high CBV nor a clear absence thereof
(between arrows) was present at the site of enhancement. The clinical
diagnosis based on continued clinical and radiological follow-up was
necrosis
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were assigned to the recurrence group and 14 lesions (41%)
to the tumor necrosis group (see Fig. 2).
The mean time to radiological progression, i.e., the
interval between SRS and lesion enlargement on follow-up
MRI scans, was not significantly different between the two
groups: 9.2 ± 2.8 months for the tumor necrosis group and
7.8 ± 3.0 months for the tumor progression group
(P = 0.21). Although the mean survival calculated from
the time of suspected recurrence (time of perfusion MRI)
was longer for the patients scored as having tumor necrosis
(13.4 ± 8.6 months) than for the tumor recurrence patients
(8.4 ± 7.1 months), this difference did not reach statistical
significance (P = 0.08), see Fig. 3 (left Kaplan–Meier
curve). However, 8 of the 20 patients with tumor recur-
rence received adjuvant treatment (5 patients underwent
neurosurgical resection, and 3 patients received radiother-
apy) and had a mean survival from time of radiological
progression of 12.8 months, against a mean survival of
5.4 months in the remaining patients, thereby prolonging
the survival of the total recurrence group. The mean overall
survival for the entire cohort (all 31 patients) is remarkably
long: 18.8 months from the moment of initial SRS.
Subjective scoring of the rCBV map
Fifteen of the 34 lesions were classified as tumor recur-
rence (Fig. 1a), and 13 lesions were diagnosed as radiation
necrosis (Fig. 1b). This left six lesions for which the rCBV
map was considered non-conclusive (Fig. 1c) (Table 1).
Logistic regression analysis was performed to calculate
how well the rCBV map diagnosis in itself is capable of
predicting actual clinical tumor recurrence, and this
showed a sensitivity and specificity of 70.0 and 92.9%,
respectively (v2 = 15.99; df = 2; P \ 0.001; R2 0.506),
and positive (PPV) and negative predictive values (NPV)
of 93.3% and 68.4%, respectively. Of the six dubious
lesions (either because of a faint ring around the lesion on
the rCBV map or the absence of a clear necrotic/very low
perfusion area) for which no diagnosis could be obtained
by subjective scoring of the rCBV map, five were judged
radiation effects, and just one was considered tumor pro-
gression, based on clinical outcome.
Quantitative rCBV measures
The mean rCBV of the recurrence group was significantly
larger than that of the tumor necrosis group for both rCBV-
WM and rCBV-GM (mean differences of -2.5 respec-
tively -1.6, see Table 2). Logistic regression analysis
yielded statistically significant models for both rCBV
measures, favoring rCBVmax-GM, with a fairly good
sensitivity and specificity ranging from 71.4 to 80.0% (see
Table 3). ROC curves, plotted for both measures (Fig. 4
and Table 3) to demarcate the optimal cutoff point and
corresponding rCBV value, yielded cutoff points of 2.00
and 1.85. This resulted in a sensitivity of 85% and corre-
sponding specificity of 71.4% for rCBVmax-WM and a
100% specificity with corresponding sensitivity of 70% for
rCBVmax-GM (Table 2). In other words, all lesions dis-
playing a maximal rCBV higher than 1.85 relative to grey
matter could be identified as tumor recurrence.
Fig. 2 Distribution of diagnoses across lesions. In total, 20 lesions
were considered to be tumor progression (6 with a histologically
confirmed diagnosis and 14 with a clinical diagnosis) and 14 to be
radiation necrosis (5 regressing lesions on further follow-up and 9
based on clinical diagnoses)
Fig. 3 Kaplan–Meier survival curves. The curve shows no significant
survival between the tumor progression (dotted line) and radiation
necrosis group (straight line); survival in months, after radiological
enlargement of the stereotactically irradiated lesion
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When the subgroup of patients with a histologically
confirmed diagnosis or with spontaneous tumor regression
on follow-up imaging was evaluated, analysis of the per-
fusion parameters demonstrated even better results with
accuracies ranging from 81.8 to 90.9% (Table 3). Using a
cutoff value of 2.0 for the rCBVmax_WM, a sensitivity of
100% was reached, and likewise a specificity of 100%
when a rCBVmax_GM higher than 1.85 was chosen.
Despite these remarkable results and even distribution, the
total number of patients is considered too small to draw any
firm conclusions.
Discussion
Enlargement of metastatic lesions after SRS, suggesting
either tumor recurrence or necrosis and affecting 20–28% of
all treated lesions, constitutes a clinically relevant diag-
nostic dilemma in patients in good functional condition and
with stable extracranial disease. The long mean overall
survival in this study of 18.8 months after SRS illustrates
this fact. In order to prevent unnecessary neurosurgical
interventions or expensive, labour-intensive and often
inconclusive imaging techniques, the efficacy of perfusion
MRI to differentiate between tumor necrosis and recurrence
Table 2 rCBV means and
group differences
Variable Necrosis (n = 14) Progression (n = 20) t P-value 95% CI
rCBV-high-WM 1.8123 4.2982 -3.459 0.002 (-3.96 -1.01)
rCBV-high-GM 0.8723 2.4672 -4.336 \0.001 (-2.36 -0.84)
Table 3 Results of logistic regression analysis (univariate)
Variable v2* Sign. Nagelkerke R2 Sensitivity (%) Specificity (%) Accuracy (%)
All lesions
rCBV map 15.992 \0.001 0.506 70.0 92.9 79.4
rCBV-high-WM 11.897 0.001 0.398 80.0 71.4 76.5
rCBV-high-GM 15.697 \0.001 0.498 75.0 78.6 76.5
rCBVmax-GM [ 1.85 21.635 \0.001 0.634 70.0 100.0 82.4
rCBVmax-WM [ 2.00 11.574 0.001 0.389 85.0 71.4 79.4
Certain diagnosis
rCBV map 11.339 0.003 0.86 83.3 100.0 90.9
rCBV-high-WM 8.604 0.003 0.725 83.3 80.0 81.8
rCBV-high-GM 7.526 0.006 0.663 83.3 80.0 81.8
rCBVmax-GM [ 1.85 9.751 0.002 0.786 83.3 100.0 90.9
rCBVmax-WM [ 2.00 6.161 0.013 0.573 100.0 60.0 81.8
Results are shown for several parameters. First the rCBV map diagnosis and the quantitative measures rCBV-high-WM and -GM, representing
the highest perfusion fraction relative to white and grey matter, were separately entered. Next, the procedure was repeated for the high rCBV
measures at their most discriminative cutoffs (1.85 and 2.0 relative to contralateral grey matter and white matter, respectively), according to the
ROC curve analysis (see Fig. 4), thereby dichotomizing the groups. *df = 2 for rCBV map and df = 1 for all other variables
Fig. 4 ROC curves. The figure displays the ROC curves for rCBV-
high-WM (straight line) and -GM (dotted line), with areas under
curves of 0.827 and 0.839, respectively. The most discriminative
cutoff point for rCBV-high-WM (*) is 2.01 with a sensitivity of
85.0% and specificity of 71.4%. For rCBV-high-GM, this point (**)
corresponds to a cutoff of 1.85 with a sensitivity of 70.0% and
specificity of 100%
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was evaluated. In our series, the detection of a nodular
fractional high perfusion area on the rCBV map (within the
contrast-enhanced lesion) or a maximum rCBV higher than
1.85 relative to grey matter was indicative of tumor recur-
rence, with a specificity of 100% and sensitivity of 70.0%.
In a small subgroup of patients with ‘‘certain’’ diagnoses,
these results even improved (i.e., the sensitivity), which
points to a possible underestimation of its recurrence
detection potential.
Current imaging modalities
Traditionally, PET, SPECT and (lately) H-MR spectros-
copy have been used to evaluate the ‘tumor recurrence—
radiation-induced necrosis’ dilemma. In general (FDG)PET
is probably the least sensitive, although better results are
reported for high grade gliomas than for metastases, for
which sensitivities between 65 and 80% are reported, with
an improvement to 86% with MRI co-registration [5, 11,
13]. The use of 11C-methionine-tracers seems to improve
these results somewhat [45, 49]. The results for HMRS and
SPECT are variable [4, 13, 30, 36, 40–42, 45], with most
papers reporting the superiority of SPECT (sensitivity and
specificity around 90–100%), but again mainly in high
grade gliomas. The results drop to sensitivities between 85
and 91% when metastases only are considered, unfortu-
nately usually without histological diagnosis [19, 43].
In particular, the pitfall of frequent false-positive find-
ings that are obtained with these techniques remains a
matter of concern [39], as this may results in unnecessary
interventions with associated morbidity or mortality. The
advantage of the method we used is the high specificity,
excluding false-positive results, and the better resolution
than on Spect, HMRS and PfalseET, since 90% of the
resected SRS-treated recurrent metastases are known to
demonstrate a mixture of tumor proliferation and necrosis
[48].
Metastasis and perfusion MRI: rationale and literature
The blood volume in tumor progression (represented by the
rCBV) is increased as a consequence of a combination of
intravascular and extravascular components: neocapillary
formation, dilatation of existing vasculature and high per-
meability of metastatic tumor vessels [3, 8–10, 25].
Although the contrast enhancement of radiation effects is
also a consequence of increased vascular permeability,
there is a clear difference between the vascular dynamics of
this increase compared to tumor progression. The transport
of blood (contrast) into necrotic areas is a consequence of
slow permeability limited by the diffusion distance (not
measured by rCBV), whereas the fast permeability seen in
(metastatic) viable tissue is determined by vessel
permeability, which is partially responsible for the
increased blood volume [31]. Areas with radiation-induced
necrosis, on the contrary, do not show an increased intra-
vascular blood volume. Hence, contrast enhancement,
which is an indicator of integrity of the blood-brain-barrier,
is not equivalent to the perfusion abnormalities measured by
the rCBV, which measures vascularity and might therefore
differentiate between necrosis and progression [20, 25].
Previous reports on SRS-treated metastases have dem-
onstrated that temporal changes in perfusion MRI
measurements are useful for differentiating radiological
responders from non-responders [23, 53]. However, in
these studies no differentiation was made between tumor
necrosis and recurrence. Others have differentiated
between these two diagnoses using perfusion MRI; how-
ever, this was only for (high grade) gliomas [17, 47].
Truong et al. used perfusion MRI in the evaluation of
progressive metastases after SRS and found a reasonable
positive predictive value of 80% in a subgroup of patients
(15/38). Although they obtained a histological diagnosis in
all patients, in contrast to our study, their measurements
were not quantified, and no true-negative lesions were
reported, despite two false-negative lesions [48]. Our
results are in agreement with the results of Koichi et al.
[21], who found the same cutoff value of 2.0 relative to
WM for differentiating necrosis from tumor recurrence
after SRS.
Perfusion MRI sensitivity
A substantial portion of the progressive metastases possibly
remain undetected given the calculated sensitivity. Part of
this underestimation might be due to an incorrect clinical
diagnosis since a considerably higher sensitivity and larger
mean difference between both groups were found in the
‘‘certain diagnosis’’ analysis. Alternatively, since the rCBV
values of treated enhancing tumor lie between the rCBV of
white and grey matter, as stated by Henry et al., the
assessment of cortical lesions is problematic, and relatively
high rCBVs are needed for a clear diagnosis of tumor
progression, thereby challenging overall sensitivity [17].
The regional cerebral blood volume (rCBV) of white
matter (especially when edema is present) is low compared
to the rCBV of grey matter, and the rCBV of treated lesions
in this study often showed intermediate values. Any (small)
increase in rCBV of treated lesions, e.g., due to radiation-
induced or inflammatory reactions of surrounding tissues,
will have a relatively higher impact on the ratio rCBV-
lesion/rCBV-WM than on the rCBV-lesion/rCBV-GM.
This could lead to a false-positive labeling of lesions as
‘progression’ based on rCBV-WM.
Secondly, lesions are often located on the junction of
grey and white matter. Since the rCBV map has a lower
884 J Neurol (2009) 256:878–887
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resolution than the conventional MRI, controversy might
arise whether the area of enhanced perfusion is due to a
progression of the metastasis in the white matter, or sur-
rounding grey matter. When the rCBV is higher than the
grey matter, the odds are that the high perfusion indeed
indicates progressive disease. On the other hand, one could
speculate that initial tumor recurrence is possibly inde-
pendent of increasing vasculature, and therefore, a
relatively early perfusion scan might miss the correct
diagnosis. In this respect, others have found serial perfu-
sion MRI more accurate in the evaluation of radiated
metastases [23, 53].
Limitations
Several limitations of the present study need to be addres-
sed. First, and most importantly, in only a small subgroup of
the patients (18%) a definite histological diagnosis was
established. This is however inherent to the clinical
dilemma, since the majority of patients present with an
asymptomatic radiological enlargement during routine fol-
low-up. For these patients with a high probability of
radiation effects, the risks of possible complications of a
resection or biopsy was deemed to outbalance the benefits
of a confirmative tissue diagnosis. The volumetric decrease
during further follow-up in a significant proportion of the
patients together with the fact that no cases of radiation
necrosis were demonstrated among the operated patients
seems to justify this wait-and-scan policy.
The authors of this study felt that judgment of the
clinical course until death, or at least 5 months after per-
forming the perfusion scan, combined with frequent
radiological evaluation justified the assignment to a diag-
nosis group in the absence of histological confirmation.
Our results obtained through a clinical diagnosis have led
to a possible underestimation of the capacity of perfusion
MRI to differentiate between both entities, since better
results were achieved for the ‘‘certain diagnosis’’ subgroup.
Secondly, our conclusions are based on a rather limited
number of patients. The group is however homogenous,
with a clinically relevant dilemma, and all data were
gathered through a consistent protocol for all patients. We
are continuing to perform perfusion MRI scans in patients
with enlarging lesions during follow-up after radiosurgery
for brain metastases, and will update the findings in due
course. Finally, since perfusion MRI was done on indica-
tion (i.e., after progressive contrast enhancement), not all
perfusion scans were achieved at the same time point after
SRS. Theoretically this poses the problem of introducing
early transient radiation effects, which occur slightly ear-
lier (within 3 months) than tumor recurrence or radiation
necrosis [18]. However, all perfusion scans in this study
were performed at least 3 months after SRS (mean
8.4 months), thereby excluding possible contamination
with transient radiation effects.
Conclusion
In conclusion, DSC MRI appears to be a useful instrument
to differentiate between tumor recurrence and radiation
necrosis after stereotactically irradiated cerebral metasta-
ses. Based on our data, a cutoff rCBV value higher than
1.85 relative to gray matter can be used to diagnose tumor
progression, as no patient with radionecrosis had values
exceeding this value. However, a value lower than 1.85
cannot be used for diagnosing radionecrosis, since some
patients with (eventual) progressive disease displayed
lower values. To further improve the sensitivity of this
modality, future research is needed to elucidate a potential
benefit of repeated perfusion MRI measurements possibly
in conjunction with other imaging modalities.
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